Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone PCA vs Oral Morphine for Severe Cancer Pain
NCT04243954Phase 2Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydromorphone in cancer pain (3 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Mean Pain Score (NRS) and Number of Breakthrough Cancer Pain (BTcP) Episodes. Started Apr 2020; status: completed.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT04243954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243954.